According to statistics from the Global Burden of Disease (GBD) compare platform, cardiovascular diseases (CVDs) and cancers were the leading causes of patient morbidity and mortality worldwide between 2016 and 2019, measured in Disability Adjusted Life Years (DALYs). Both of these conditions can co-exist in a single patient and are linked to risk factors, such as dyslipidemia and hypertension (HTN). The simultaneous affliction of patients with both conditions mandates the co-administration of cardiac and oncologic drugs, which in turn leads to drug-drug interactions (DDIs), either pharmacodynamic (PD) or pharmacokinetic (PK). These DDIs, as a side effect, promote the development of more risk factors within these patients. In this thesis, I establish and highlight a potential causative link between these DDIs and the increased DALYs associated with CVDs and cancer, demonstrating several examples of combinative regimens that induce specific risk factors, such as HTN. Based on the information reviewed in this paper, the high DALYs in cardio-oncology patients may be partly iatrogenic, caused by DDIs, and further research is mandated to explore better combinative regimens with fewer adverse effects.